Nu-Med Plus (NUMD) Long-Term Debt Repayments (2012 - 2017)

Nu-Med Plus' (NUMD) quarterly Long-Term Debt Repayments came in at -$27500.0 in Q1 2017, down 125.7% year-on-year from $107000.0 in Q1 2016, and little changed quarter-over-quarter from -$27500.0 in Q4 2016.

Nu-Med Plus (NUMD) Long-Term Debt Repayments (2012 - 2017) Analysis & Trends

Nu-Med Plus has disclosed Long-Term Debt Repayments across 3 years of filings, most recently posting -$27500.0 for Q1 2017.

  • Long-Term Debt Repayments for Q1 2017 came in at -$27500.0, down 125.7% year-over-year; the trailing twelve-month figure through Dec 2017 was -$27500.0 (changed 0.0% YoY), and the FY2017 annual result was -$27500.0, changed 0.0% from the prior year.
  • Long-Term Debt Repayments came in at -$27500.0 for Q1 2017 at Nu-Med Plus, roughly flat from -$27500.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $107000.0 in Q1 2016 to a low of -$107000.0 in Q2 2016.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Abbott Laboratories 152.92 Bn 146.27 Bn 6.27 Bn 1.42 Bn
2 Stryker 119.50 Bn 116.62 Bn 3.81 Bn 1.00 Bn
3 Medtronic 102.71 Bn 94.54 Bn 5.76 Bn -
4 Boston Scientific 69.72 Bn 68.51 Bn 3.61 Bn -
5 Edwards Lifesciences 49.24 Bn 45.57 Bn 1.29 Bn -
6 GE HealthCare Technologies 29.74 Bn 27.67 Bn 1.98 Bn -
7 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
8 Dexcom 28.96 Bn 27.84 Bn 750.30 Mn -
9 Steris 20.31 Bn 19.88 Bn 697.10 Mn -
10 Nu-Med Plus - - - -

Historic Data

Download Data
DateValue
Mar 31, 2017 -27,500.00
Mar 31, 2017 -27,500.00
Dec 31, 2016 -27,500.00
Dec 31, 2016 -27,500.00
Jun 30, 2016 -107,000.00
Jun 30, 2016 -107,000.00
Mar 31, 2016 107,000.00
Mar 31, 2016 107,000.00
Dec 31, 2012 1,908.00
Dec 31, 2012 1,908.00
Sep 30, 2012 3,400.00
Sep 30, 2012 3,400.00
Jun 30, 2012 -1,700.00
Jun 30, 2012 -1,700.00